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ASSOCIATION BETWEEN VITAMIN D INTAKE AND CORONARY HEART DISEASE 
MORTALITY AMONG MEN AND WOMEN WITH CORONARY HEART DISEASE IN 
KUOPIO, FINLAND 
 
Vitamin D can be derived from quite limited amount of foods, from exposing the skin to the 
sun or by supplementing with tablets. CHD is a common disease in the world with increased 
mortality from the early 20
th
 century. Previous studies have investigated the association 
between vitamin D intake and CHD mortality. However, the results are inconclusive, 
indicating the need for continued research. 
  
Vitamin D intake of 415 patients with CHD were analyzed to predict CHD mortality. During 
the 5 year follow up, there were 16 CHD deaths. After adjusting for age and sex there was no 
association between vitamin D intake and CHD death with RR 1.10 (95% confidence interval 
(CI) 1.04-1.17,p= 0.677), CVD death, 1.07 ( 95% CI 1.02-1.12, p=0.578), and total death RR 
1.05( 95% CI 1.00-1.10, p=0.266. 
 
The association remained insignificant after further adjustment for known confounders. There 
was no association between different groups of vitamin D intake and the three endpoints: 
total, CVD and CHD mortality (p for trend across groups: 0.30, 0.74 and 0.89, respectively). 
After adjustment for age, gender and other confounders, those in the vitamin D group of 5-7 
µg/day had RR of 1.27 (95% CI: 0.52,3.12) of  total death, compared to those in the lowest 
group of < 5 µg/day (p for trend across groups: 0.30).  
 
Results from this study suggest that there is no association between vitamin D intake and 
CHD mortality in subjects with existing CHD . The clinical implication of this study is that 
vitamin D intake among men and women with CHD could benefit from further research.  
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ABBREVIATIONS 
 
AMI                    Acute myocardial infarction.  
AMIS                  Acute myocardial ischemia.  
BP                       Blood pressure.  
CVD                    Cardiovascular disease.  
CHD                    Coronary heart disease.  
CAD                    Coronary artery disease.   
CABG                 Coronary artery bypass grafting.  
CI                        Confidence interval. 
EUROASPIRE    European action on secondary prevention through intervention to reduce        
                  events. 
HF                        Heart failure.  
HDL                     High density lipoprotein.  
25(OH)D              25 hydroxyvitamin D. 
IHD                      Ischemic heart disease.  
IOM                     Institute of medicine.  
LDL                     Low density lipoprotein.  
MI                        Myocardial infarction.  
NHANES             National Health and Nutritional Examination.  
PTH                     Parathyroid hormone. 
PTCA                  Percutaneous transluminal coronary angioplasty.   
RDA                    Recommended dietary allowance. 
RR                       Risk ratio.  
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SBP                     Systolic blood pressure. 
WHO                   World health organization.   
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1. INTRODUCTION 
 
According to the World Health Organization (WHO), almost 23.6 million deaths will be attributed 
to cardiovascular diseases (CVD), mainly stroke and heart diseases by the year 2030. CVDs include 
coronary heart disease (CHD), cerebrovascular disease, peripheral arterial disease, rheumatic heart 
disease, congenital heart diseases, deep vein thrombosis and pulmonary embolism. The behavioral 
risk factors of CVD are smoking, physical inactivity and harmful use of alcohol. The metabolic risk 
factors are high blood pressure, raised blood glucose, raised blood lipids, overweight and obesity. 
Underlying factors include social, economic and cultural change manifested by globalization, 
urbanization, and population ageing. Other determinants include poverty, stress and hereditary 
factors (WHO 2011). 
CHD is among the leading causes of death in industrialized countries, with higher rates in men than 
in women, although as women age, CHD related mortality increases. Nutritional factors have been 
shown to play a major role in the etiology and management of CHD. In recent years, scientists have 
continued to discover sources, roles and purpose of vitamin D in the body (Ross et al. 2011). 
The earliest evidence on the importance of vitamin D to human health began with the industrial 
revolution in Europe. This was a period characterized with massive migration to the cities, leading 
to congestion and environmental pollution. Consequently, children had inadequate exposure to 
sunlight as the structures were squeezed and without adequate sun exposure. This was associated 
with increased prevalence of rickets in children (Holick 2004). Similar observations were made in 
the United States. Towards the end of the 20
th
 century, reported cases of rickets had spread all over 
the world.   
Vitamin D deficiency and rickets continued to be of interest, with evidence showing reduced 
prevalence of rickets in 1930s, when fortification of foods with the vitamin was introduced.(Holick 
2004).  
Studies investigating the association between vitamin D and CHD began in the 1970s. One of the 
earliest studies conducted in Denmark in 1978 where circulating 25 hydroxyvitamin D (25(OH) D) 
concentration was measured in 128 patients admitted with ischemic symptoms and 409 controls. 
10 
 
 
Findings showed that 25(OH)D concentrations were lower in ischemic patients at 58.75 nmol/L,  
compared to controls who had 72 nmol/L (Leu & Giovannucci 2011). A nested case-control study 
of patients with myocardial infarction (MI) using data from the Tromso Heart Study in northern 
Norway using 30 cases and 60 matched controls, reported a slightly lower 25(OH)D level in cases 
59 nmol/L compared to controls 63.5 nmol/L. These two studies suggested that there were effects 
of low vitamin D intake on patients with heart complications. Despite these findings, few human 
studies with regard to vitamin D and its relation to CHD have been  reported (Leu & Giovannucci 
2011).  
There is continued interest in vitamin D’s broad spectrum of health benefits and outcomes. The 
relationship between vitamin D and bone health has been well established (Ross et al. 2011). This 
paved the way for research on  investigating relationship between vitamin D and other health 
outcomes. However, evidence concerning the relationship between vitamin D intake and CHD is 
still inconclusive with scientist recommending more studies and clinical trials. 
 In this study we seek to investigate the existence of an association between vitamin D and CHD 
mortality in patients who have existing CHD. 
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2. LITERATURE REVIEW 
In the 1980s and 1990s several observations on the relation between vitamin D and CHD suggested 
that vitamin D could explain differences in mortality from ischemic heart disease (IHD). The 
National Health and Nutritional Examination Surveys (NHANES) conducted between 1988 and 
2004 showed that individuals with vitamin D deficiency had a higher risk of reporting incidences of 
heart failure (HF) and MI than those individuals with higher intake of vitamin D (Judd & 
Tangpricha 2009).  
Randomized controlled trials done on German elderly women concluded that little amounts of 
vitamin D 400IU per day could reduce systolic blood pressure (Pfeifer et al. 2001). On the contrary, 
the Women’s Health Initiative (WHI) showed no significant difference with regard to diastolic 
blood pressure in women randomized to consume either calcium or vitamin D supplements (400 IU 
per day) at the end of 7 years of follow up (Scragg et al. 1995). A review concluded that vitamin D 
insufficiency is common in the world and that the current evidence does not strongly support 
screening for vitamin D deficiency in patients with CHD or those who are at risk of CHD (Judd & 
Tangpricha 2009).  
A meta analysis done on vitamin D and cardiovascular outcomes found that trial data available are 
unable to demonstrate a statistical significant reduction in mortality and CHD risk associated with 
vitamin D intake (Elamin et al. 2011). Similar results were observed in another meta analysis by 
Grandi et al. (2010) which concluded that data from prospective investigations suggest an inverse 
association between vitamin D intake and CHD and recommended that more research is needed.  
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2.1. Vitamin D 
Vitamin D is a fat-soluble vitamin obtained endogenously through the skin and is induced by ultra 
violet radiation (Figure 1).  
 
 
         Figure 1:Pathway of vitamin D synthesis in the body (LoPiccolo & Lim 2010). 
Ultraviolet B at a wavelength of 300±5 nm converts 7-dehydrocholesterol (pro-vitamin D3) into 
pre-vitamin D3 in the basal and suprabasal layers of the epidermis. Pre-vitamin D3 then undergoes 
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non-enzymatic isomerization to form cholecalciferol, known as vitamin D3. Cholecalciferol enters 
the circulation and is transported by vitamin D binding protein to the liver, where hydroxylation by 
25-hydroxylase to 25(OH)D occurs. In the end 25(OH)D is transported by vitamin D binding 
protein to the kidney where hydroxylation by 1α-hydroxylase to 1, 25-dihydroxyvitamin D [1α, 
25(OH) 2 D] occurs, yielding the hormonally active form of vitamin D (LoPiccolo & Lim 2010).  
Vitamins D2 (ergocalciferol) and D3 are also widely available in the form of over-the-counter 
dietary supplements. Vitamin D reduces CHD risk by inhibiting vascular smooth muscle 
proliferation, regulating blood pressure and glucose metabolism and reducing inflammation 
(Manson 2010). Studies have suggested that vitamin D2 is inferior to vitamin D3 in raising serum 
25(OH) D, and may even suppress the endogenous formation of 25(OH )D and 1α,25(OH)2D 
(LoPiccolo & Lim 2010). 
According to the Institute of Medicine (IOM) in the United States the estimated average 
requirement per day for vitamin D in 2010 was 400 IU/day for all ages. The recommended dietary 
allowance and upper level intake in children ranges from 600-2500 IU/day (1 to 3 years) and 600–
3000 IU/day (4 to 8 years), respectively (Institute of Medicine 2010).  
The rest of the population aged from 9 to 70 have a recommendation of 600 IU/day as the 
recommended dietary allowance (RDA) and an upper tolerable level intake of 4000 IU/ day 
(Institute of Medicine 2010). There has been no consensus on the cut points for vitamin D 
deficiency and its definition has not been well defined. The current International Osteoporosis 
Foundation (IOF) guidelines define it as having serum 25(OH)D of less than 25 nmol/L (McGreevy 
& Williams 2011). 
A vitamin D concentration of 50 nmol/L is considered a normal/ sufficient level of  circulating 
25(OH)D (Holick 2005). Wallis et al. (2008) mentions that a 25(OH)D level of >75 nmol/L is 
sufficient and that the measurement of parathyroid hormone (PTH) alone is not a reliable measure 
of vitamin D adequacy especially in patients with chronic renal failure or calcium insufficiency. 
Dietary sources of vitamin D include oily fish  such as (salmon, mackerel, and herring ), egg yolk 
and some mushrooms. Cod liver oil that is extracted from fish is also a good source of the vitamin. 
In the United States milk, some juices, some breads, yoghurts, cereals, chocolate mixes and cheese 
14 
 
 
are fortified with vitamin D. There are also multivitamins available in various amounts 400 to 
50000 IU  (LoPiccolo & Lim 2010, Holick & Chen 2008). 
In Finland vitamin D sources are mainly from fish, fortified dairy products and margarine (Pietinen 
et al. 2010). The fortification of fat spreads with vitamin D in Finland started in the 1950s and 
fortification of milk products began in 2003. This has greatly increased vitamin D intake but 
surveys show that the intake are still inadequate in both men and women (Pietinen et al. 2010). 
2.1.1. Risks of vitamin D deficiency 
Vitamin D deficiency is common in the northern latitude. This could be attributed to the low 
amounts of UVB light during winter. A British study with 7437 participants, found that half of the 
participants had 25(OH)D concentration of below 40 nmol/L during winter and spring (McGreevy 
& Williams 2011). A sunscreen with a sun protection of 15 absorbs incident UVB radiation and 
could reduce vitamin D3 synthesis by 99% (McGreevy & Williams 2011). Aging is also associated 
with decreased vitamin D3 level due to the reduced cutaneous production of vitamin D (McGreevy 
& Williams 2011). Members of some religions that cover their body, and also women and children 
in geographical areas with long winters, institutionalized persons, and HIV infection drugs that 
increase the catabolism of 25(OH)D through induction of CYP450 system also increase the risk of 
vitamin D deficiency (McGreevy & Williams 2011).  
Vitamin D deficiency could lead to deranged metabolism in the body, causing conditions such as 
high blood pressure and adult onset diabetes mellitus (Holick & Chen 2008), as shown in Figure 2. 
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Figure 2: Pathways through which vitamin D leads to CHD risk (Artaza et al. 2009). 
 
Vitamin D deficiency could lead to oxidative stress, immune dysfunction, hyperthyroidism, 
hypocalcaemia, inflammation, thrombosis and hypertension. These complications could lead to 
vascular dysfunction and atherogenesis and consequently CHD (Artaza et al. 2009). 
An analysis to investigate prevalence of vitamin D deficiency and the relation of Vitamin D intake 
to prevalent and incident CHD risk factors and disease showed that vitamin D deficiency was 
associated with CHD (Anderson et al. 2010).  
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The continued worsening trend of nutritional insufficiency and the improving knowledge of the non 
hormonal actions of vitamin D and its metabolites have increased the interest in the synthesis, 
metabolism, and action of vitamin D. Vitamin D deficiency has continued to be linked to HBP, MI, 
stroke, diabetes, congestive heart failure, peripheral vascular disease, atherosclerosis and 
endothelial dysfunction (McGreevy & Williams 2011, Gouni-Berthold et al. 2009, Michos & 
Melamed 2008). Similarly, a population study conducted in Israel supported the fact that low 
25(OH)D intake is associated with CHD (Steinvil et al. 2011). 
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Table 1: Serum vitamin D and coronary heart disease risk, and dietary vitamin D and CHD mortality. 
Name of study, author, Type of study  Population type  Population size, n  Results 
Parathyroid hormone and vitamin 
D markers for cardiovascular and 
all cause mortality in heart failure 
by Schierbeck 2011 
Prospective follow cohort Male and female HF 
outpatients were 
followed-up for 3½ 
years. 
148   Vitamin D deficiency  was prevalent 
in 43% of the population and vitamin 
D was independently associated HF.  
Vitamin D status and the risk of 
cardiovascular disease death by 
Kilkkinen 2009 
Prospective cohort study. Finnish adults 6219 participants  free of CHD at 
baseline with measured serum 
25(OH)D intake, 27.1 years of 
follow up 
There were 640 CHD deaths, with 
low vitamin D intake being associated 
with CHD events. 
Vitamin D intake and risk of 
cardiovascular disease in US men 
and women by Sun Q 2011. 
Prospective cohort study American adults  118,864 men free of CVD at 
baseline 
9886 cases of CHD was reported. A 
higher intake of vitamin D was 
associated with a lower incidence of 
CHD in men but not in women.  
25 hydroxyvitamin D and risk of 
myocardial infarction in men by 
Giovannucci 2008  
Prospective study. Aged 40 to 75 free of 
CVD at baseline  
18225 men  After 10 year follow up 454 men 
developed CHD with low serum 
vitamin D concentration being 
associated with CHD. 
Relationship with 25 
hydroxyvitamin D with all cause 
and cardiovascular disease 
mortality in older community 
dwelling adults by Semba 2010 
Prospective cohort study.  men aged >= 65years 1006 followed up for 6.5 years. Individuals with low serum 25(OH)D 
were at a higher risk of all-cause and 
CHD mortality. 
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 Low serum hydroxyvitamin D 
levels are associated with 
increased mortality risk in a 
general population: the Tromso 
study by Hutchinson 2010 
Prospective cohort study. Male and female The study had 7161 participants 
from the Tromso study. 
During a follow-up period of 11.7 
years, 1359 (19.0%) participants died. 
Low serum 25(OH)D intake were 
associated with increased CHD 
mortality. 
Association of serum 25 
hydroxyvitavitmin D with the 
risk of death in a general older 
population in Finland by 
Virtanen 2011 
Prospective cohort study. Men and women aged 
between 53 to 73 
without CHD at the 
beginning of the study. 
 
552 men and 584 women 
Low concentration of serum 
25(OH)D was associated with CHD 
deaths.  
Serum and dDietary vitamin D and 
cardiovascular disease risk in 
elderly men by Messenger 2011 
 Prospective cohort study Evaluating between 
serum and dietary 
vitamin D intake and 
incidence of CHD 
3094 men There were 371 CHD cases, there was 
no association between vitamin D 
concentration deficiency compared to 
sufficiency with CHD incidence. 
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 2.2 Vitamin D and coronary heart disease risk 
In recent years, there has been an increase in interest to evaluate other potential functions of vitamin D 
and particularly with its relation to CHDs. Few studies have demonstrated an increased risk for CHD 
death in individuals with vitamin D deficiency (Virtanen et al. 2011). Some experimental studies have 
suggested  several CHD protective mechanisms such as anti-atherosclerotic, anti-inflammatory and 
direct cardio protective actions (Gouni-Berthold et al. 2009, Borges et al. 2011, Pilz et al. 2009).  
On the contrary, other epidemiologic studies have found an inverse association between vitamin D 
deficiency and prevalence of CHDs as well as individual cardio-metabolic risk factors (Anagnostis et 
al. 2010). There has also been contrasting findings with other studies documenting that there exists no 
relationship between serum 25(OH)D and the incidence of CHD (Messenger et al. 2011).  
 In a study that prospectively analyzed large electronic medical records database to determine the 
prevalence of vitamin D deficiency and its intake to prevalent and incidence of CHD risk factors, the 
findings demonstrated that vitamin D intake were highly associated with CHD at (p< 0.0001) 
(Anderson et al. 2010). Conclusively vitamin D status can lead to CHD incidence whether CVD status 
of the participants is established at the beginning or at the end of the study. The database contained 
41,504 patient records with at least one measurement of vitamin D intake.   
Using data from the Health Professionals Follow up Study, Giovannucci (2008) concluded that low 
25(OH)D concentrations were associated with an increased risk of CHD (Table 1). Similarly, previous 
cross-sectional studies have reported that vitamin D deficiency is associated with increased risk of 
CVD including hypertension, HF and IHD (Judd & Tangpricha 2009).  
2.2.1 Vitamin D and blood pressure 
Hypertension is a growing health concern and is postulated to affect 1.6 billion people worldwide by 
the year 2025. A review concluded that there is evidence that supports the association of vitamin D 
and blood pressure (Martini & Wood 2008). Another review also showed that vitamin D helps in the 
treatment of hypertension (Wallis et al. 2008). The result showed that there was a fall in diastolic and 
systolic blood pressure after exposure to sunlight 3 times a week daily for 6 weeks (Wallis et al. 2008).  
20 
 
 
Wang et al. (2008) investigated the association between intake of dairy products, calcium and vitamin 
D and the occurrence of hypertension in 28,886 US women aged 45 years and above. The results of 
the study showed that there is an association between dietary vitamin D and hypertension.  
A similar study of two prospective cohort studies with 613 men from Health Professionals Follow up 
Study and 1198 women from the Nurses’ Health Study investigating the association between plasma 
25(OH) D and risk of incident hypertension concluded that there was an inverse relation between 
25(OH) D and risk of incident hypertension (Forman et al. 2007).  
         2.2.2 Vitamin D and parathyroid hormone 
Individuals with excessively high levels of PTH that accompany primary or secondary 
hyperparathyroidism, and patients with end stage renal disease, have increased the risk of CHD 
mortality(Hedback & Oden 1998, Nilsson et al. 2002). 
There are few reports about PTH levels and risk of CHD mortality in older adults without kidney 
disease. One study reported an association between higher PTH levels and increased risk of CHD 
mortality among institutionalized older adults who did not have primary hyperparathyroidism. The 
study had 842 subjects (82 men and 660 women) and after a follow up period of 11months 345 died 
(Sambrook et al. 2004). Another study demonstrated an increased risk of all-cause and CHD mortality 
with higher PTH levels among 978 men in the community (Hagstrom et al. 2009). 
2.3 Vitamin D supplements and coronary heart disease 
Randomized controlled trials with vitamin D supplementation have found some effect on CHD risk 
reduction. A study that randomized British men with vitamin D3 100,000 IU/day given every four 
months for over 5 years, showed that there was a reduction in CHD events and mortality (Manson 
2010). Women’s Health Initiative study with 36,282 post-menopausal women participants aged 50 to 
79 were tested with vitamin D3 (400 IU/day) for a seven year period. The study revealed that there 
was no increase or decrease in CHD mortality with vitamin D supplementation (Hsia et al. 2007). 
2.4  Serum Vitamin D level  and coronary heart disease mortality 
Currently there are ongoing investigations as to whether there exists a relation between serum vitamin 
D level and CHD mortality in patients with heart conditions (Judd & Tangpricha 2009). However, a 
little evidence demonstrating the association is available (Zittermann et al. 2009). Accumulating 
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evidence from several non-randomized studies also indicate that deficient 25(OH)D concentrations are 
associated with excess CHD mortality in the general population (Zittermann et al. 2009). 
A study investigating whether low serum 25(OH)D concentrations are associated with an increased 
CHD mortality concluded that a positive relationship exists. Hutchinson and colleagues (2010) 
similarly found an association between serum 25(OH)D concentrations and CHD mortality. The study 
included both male and female participants hence it is possible to generalize the findings to a wider 
population (Hutchinson et al. 2010). Another study showed that, vitamin D deficiency was prevalent in 
43% of the population and concluded that vitamin D was independently associated with CHD 
mortality (Schierbeck et al. 2011) ( Table 1). 
Contrary to the above findings, other studies have found that both low and high serum 25(OH)D 
should not be encouraged. This was evident in the Uppsala Longitudinal Study investigating the 
association between plasma 25(OH)D and mortality with a sample of 1194 adults. Approximately 50% 
higher total mortality rate was observed among men in the lowest 10% and the highest 5% of plasma 
25(OH)D concentrations compared with intermediate concentrations. The conclusion was that both 
high and low concentrations of plasma 25(OH)D are associated with elevated risks of CHD mortality 
(Michaelsson et al. 2010). 
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3 AIM OF THE STUDY 
 
The main aim of this study was to evaluate the association between dietary vitamin D intake and 
risk of CHD mortality in men and women with established CHD.  
This study also investigates the association between vitamin D intake and CVD and total mortality.  
 
 
 
HYPOTHESIS 
There exists an association between sufficient vitamin D intake with reduced CHD, CVD and total 
mortality. 
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4. SUBJECTS  
Our study evaluates participants from the European Action on Secondary Prevention through 
Intervention to Reduce Events (EUROASPIRE) study. This is a prospective cohort study with subjects 
having clinically established CHD, and admitted at the Kuopio University Hospital. The follow up 
period was 5 years (Erkkilä et al. 2003).   
The Finnish cohort of the EUROASPIRE study comprised 415 patients (285 men, 130 women) with 
clinically established CHD, between 1991–1994 and who were aged <71 years at the time of hospital 
admission. Discharge lists, cardiac surgery and coronary angiography registers were used to 
retrospectively categorize patients into four categories (Erkkilä et al. 2003). 
1. Patients going through their first elective or emergency coronary artery bypass grafting 
(CABG). 
2. Those having their first elective or emergency percutaneous transluminal coronary 
angioplasty (PTCA) but with no previous CABG.  
3. Those having their first or recurrent acute myocardial infarction (AMI) but with no CABG 
or PTCA. 
4. Those admitted with known symptoms of acute myocardial ischemia (AMIS) but with no 
confirmation of AMI and with no record of CABG, PTCA, or AMI. 
The researchers identified 125 patients with CABG, PTCA, and AMIS and 156 with AMI. The 
baseline examination was conducted in 1995. 
The following number of patients from each category participated in the study: CABG, 109; PTCA, 
106; AMI, 101; and AMIS, 99; with an overall participation rate of 82%, a total of 415 patients were 
included in the study. The Finnish center was the only one of the EUROASPIRE centers to carry out 
detailed dietary studies and measurements. All patients gave their approved consent to be part of this 
study and the study was approved by the Ethics Committee of the University of Kuopio (Erkkilä et al. 
2003).  
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5. METHODS 
 5.1 Interview and examination 
Structured questionnaires were used to conduct patient interviews with information on  demographics, 
including years of schooling; smoking habits; and use of drugs. Measurements taken included, weight, 
height, waist circumference, hip circumference and blood pressure (BP). Weight was measured while 
the subjects wore light clothing with no shoes. Body mass index (BMI) was calculated as weight 
(kg)/height (m
2
) and waist circumference was measured midway between the lower rib margin and the 
iliac crest. Hip circumference was measured at the point yielding the maximum circumference over the 
buttocks (Erkkilä et al. 2003).  
An automatic digital sphygmomanometer (Takeda UA 731; A&D Co.Ltd, Abingdon, United 
Kingdom) was used to measure BP while the subjects were in a sitting position and after they had 
rested for 5 min. Non smoking status was validated by performing a breath carbon monoxide 
measurement (≤ 10 parts per million) (Bedfont Scientific EC 50,Sittingbourne, United Kingdom). The 
diagnosis of diabetes was based on previous diagnosis by a physician or if their fasting plasma glucose 
concentration was ≥ 7 mmol/l (Erkkilä et al. 2003). 
 5.2 Food records 
A 4-day food record (3 weekdays and 1weekend day) was completed at home by the patients and they 
estimated the amounts of foods consumed using portion sizes listed in a booklet. The food records 
were returned during the interview, and all records were checked by a clinical nutritionist and missing 
information was completed if necessary. MICRO-NUTRICA dietary analysis program (version 2.0; 
Finnish Social Insurance Institution, Turku, Finland), was used to calculate nutrient intakes (Erkkilä et 
al. 2003). 
 5.3 Laboratory measurements 
Collection of blood samples was done between 0800 and 1000 after patients had fasted for 12 hours. 
Serum lipids, lipoproteins, low density lipoprotein (LDL) and high density lipoprotein (HDL) were 
then analyzed. The serum samples were stored at -70 degrees until they were ready for analysis while 
the fresh serum was used to measure the serum total and lipoprotein lipids. Ultracentrifugation  for 18h 
at 4 degrees, 144 000 by g, and density of 1.006 kg/L to remove VLDL, then dextran sulfate- 
magnesium chloride was used to precipitate LDL from the fluid (Penttila et al. 1981). Finally, HDL 
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was analyzed from the remaining fluid. Calculation of LDL cholesterol was done by subtracting the 
amount of HDL from the fluid containing HDL and LDL cholesterol (Erkkilä et al. 2003). 
Commercial kits (kits 237574 and 701904; Boehringer GmbH, Mannheim, Germany) and a Kone 
Specific Clinical Analyzer (Kone Ltd, Espoo, Finland) were used to analyze cholesterol in the whole 
serum and in separated lipoproteins and serum triacylglycerols. Serum lipids were analyzed using 
standardized enzymatic methods. Amperometric enzymatic method (GlucoseAuto & Stat GA 110 
analyzer; Daiichi Co, Kyoto, Japan) was used to analyze plasma glucose (Erkkilä et al. 2003).  
5.4 Endpoint ascertainment 
The date of the earliest event or the end of the follow-up period (30 April 2001 for deaths and 31 
December 2000 for hospitalizations) was the censoring date. The endpoints included deaths from all 
causes, CVD and CHD.  
CHD deaths included codes 120-125 from the International Classification of Diseases, 10
th
 version, 
and CVD deaths included codes 120-28, 160-69, G45 and G46. Computer linkage of Finnish social 
security numbers to the national death register (Statistics Finland, Helsinki) was used to ascertain 
deaths and to retrieve copies of death certificates. The national hospital discharge registers of the 
National Research and Development Centre for Welfare and Health on the basis of social security 
numbers was used to obtain data on AMIs, strokes, and revascularization procedures, medical records 
were also obtained (Erkkilä et al. 2003).  
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6. STATISTICAL ANALYSIS 
 
Statistical analysis was done using SPSS for WINDOWS version 17. Test for normality was 
done using the Kolmogorov – Smirnov test. Frequencies, percentages, means and standard 
deviations of the various variables were analyzed to describe the data.  
Chi- square test was used to explore the relationship between categorical variables. The 
difference in baseline characteristics was analyzed using non- parametric tests. One way analysis 
of variance (ANOVA) was used to compare means among groups. 
Vitamin D intake was divided into three categories of less than 5 µg/day, 5 µg/day to 7 µg/day 
and greater than 7 µg/day. Education was divided in to those who studied for less than 8 years, 
9–11 years and more than 11 years. Elevated BP was defined as systolic blood pressure (SBP) of 
over 140mmHg and diastolic blood pressure more than 90mmHg. Current smokers, diabetes, the 
use of beta blockers, lipid lowering drugs, aspirin and other anti-platelet drugs, ACE inhibitors 
and family history of CHD were all categorized as yes or no.  
The Cox proportional hazard model was used to assess relative risks of different endpoints. 
Vitamin D intake was entered in the model as a categorical variable after it was classified in 
three groups.  
The model was first adjusted for age and sex only. The second model was then adjusted for sex, 
age, diagnostic category (CABG or PTCA compared with AMI or AMIS), total serum 
cholesterol concentration, triglycerides concentration, BMI, diabetes mellitus, education and 
energy intake. P value of less than 0.05 was considered statistically significant. 
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7. RESULTS 
7.1 Baseline characteristics 
The participants had a mean age of 60 years, with more than half being men (66.9%). Most of the 
participants at baseline were overweight, with a mean waist hip ratio of 0.93. The mean BMI was 
28.2 kg/m
2
, 13.2% of the participants had diabetes and 81.9% had a family history of CHD at 
baseline (Table 2). During the follow up period, there were a total of 34 deaths with of which 16 
were due to CHD. The mean energy intake was 1731kcal/day. The mean vitamin D intake was 
5.3µg/day and a maximum of 24µg/day.   
Other baseline characteristics of the study participants are shown in table 2. 
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Table 2. Baseline characteristics of the CHD patients (n = 415) 
 
LDL (low density lipoprotein), HDL (high density lipoprotein ), CABG ( coronary artery bypass grafting ),PTCA (percutaneous 
transluminal coronary angioplasty ),AMI (acute myocardial infarction), AMIS (acute myocardial ischemia), CHD (coronary heart 
disease). 
 
Variables  Mean or n (%) ±SD Minimum Maximum 
Age(years) 60.9 8.41 25.0 73.9 
Sex                                         Male             
                                               Female          
66.9% 
 33.1% 
   
Body mass index (kg/m²) 28.2 4.0 16.7 45.5 
Waist to hip ratio 0.93 0.07 0.72 1.09 
Years of formal education       ˂8 years 
                                                 9- 11 years 
                                                  ≥ 12 years 
270 ( 65.1 ) 
92 ( 22.2 ) 
53 ( 12.8 ) 
   
Current smoker  51 (20.1%)    
Smoking ( years)  23.4  11.8 0 60.00 
Systolic blood pressure ( mmHg )                     141 22 82 204 
Diastolic blood pressure ( mmHg) 82 12 44 140 
Vitamin D intake (mg/day) 5.3 3.9 0.4 24.3 
Energy(kcal/day ) 1731  511 635 3410 
                                                                                  LIPIDS 
Serum total cholesterol (mmol/l) 6.12 1.18 2.13 11.96 
LDL cholesterol (mmol/l) 4.25 1.04 1.28 10.83 
HDL cholesterol(mmol/l) 1.22 0.29 0.47 2.77 
Triglycerides(mmol/l) 1.94 1.50 0.60 23.12 
                                                                               DIAGNOSES AT BASELINE 
CABG 109 ( 26.2% )    
PTCA 106 ( 25.5% )    
AMI 101( 24.3% )    
AMIS 99 ( 23.8% )    
Diabetes diagnosed or plasma glucose ≥ 7mmol/l 70 (13.2%)    
Family history of CHD 339 (81.9%)    
                                                                                 USE OF MEDICATION 
Lipid lowering drugs 59 (11.1%)    
ACE inhibitors 72 (17.3%)    
Beta blockers 323 (77.8%)    
Aspirin and other anti-platelet 341 (82.2%)    
                                                                            EVENTS DURING FOLLOW UP 
CHD deaths 16 (47.05%)    
CVD deaths 18 (52.94%)    
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7.2 Characteristics of CHD patients in vitamin D groups 
  After categorizing CHD patients according to amount of vitamin D intake per day, it was 
observed that a majority consumed less than 5µg/day in both genders. Similarly, it was noted that 
regardless of the years of education, most of the participants consumed less than 5µg/day.  
Participants who had chronic illnesses such as diabetes and hypertension were also noted to 
consume insufficient amount of vitamin D. It was also noted that 69.4% of the patients who were 
current smokers had a low vitamin D intake of less than 5µg/day and 55.1% had a family history 
of CHD. 
Details of other CHD patients’ characteristics are shown in table 3. 
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Table 3. Characteristics of the CHD patients in vitamin D groups.                                                                   
Categorical variables 
 
< 5 µg/day  
n= 232 
5- 7 µg/day                 
n = 83 
> 7 µg/day            
n = 86 
Sex 
Men 
Women 
 
 51.6% 
 72.4% 
 
 25.1% 
 10.6% 
 
 23.3% 
 17.1% 
Education 
<8yrs 
9- 11 
>12 
 
57.6% 
 65.9% 
45.1% 
 
19.5% 
14.8% 
37.3% 
 
22.9% 
19.3% 
17.6% 
Current Smoking  69.4% 18.4% 12.2% 
Diabetes 65.7% 20.9% 13.4% 
High blood pressure  56.4% 23.3%  20.3% 
Beta blockers 56.4% 22% 21.7% 
Lipid lowering drugs 54.7% 24.8% 20.5% 
Aspirin and platelet drugs 57.2% 20.7% 22.2% 
ACE inhibitors 49.3% 24.6% 26.1% 
Family History of CHD 55.1% 24.5% 20.4% 
Age (years) 60.6 ± 8.7 60.5 ± 8 61.7 ± 8.2 
Body mass index (kg/m²) 28.3 ± 4.3 27.8 ± 3.5 28.2 ± 3.7 
Waist to hip ratio 0.93 ± 0.08 0.95 ± 0.06 0.93 ± 0.07 
Waist measured (cms) 92  ± 10 93  ± 9 93 ± 9 
Total cholesterol (mmol/l) 6.16 ± 1.18 6.01 ± 1.2 6 .06 ± 1.09 
LDL cholesterol (mmol/l) 4.25 ± 1.08 4.20 ±1.03 4.30 ± 0.98 
HDL cholesterol (mmol/l) 1.23 ± 0.29 1.20 ±0.30 1.25 ± 0.28 
Triglycerides (mmol/l)  2.0 5 ± 1.78 1.20 ±1.14 1.67 ± 0.85 
Systolic blood pressure(mmHg) 141.8 ± 22.7 138.9 ± 20.0 140.1 ± 23.5 
Diastolic blood pressure(mmHg) 82.8 ± 12.8 80.8 ±11.1 81.9 ± 11.9 
All values are mean SD or percentages 
CHD (coronary heart disease), CVD (cardiovascular diseases). 
LDL (low density lipoprotein), HDL (high density lipoprotein) 
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7.3 Vitamin D intake and risk of death 
The first cox model was adjusted for age and sex for the all endpoints (total death CVD death 
and CHD death) with continuous vitamin D intake as exposure. The results show that there is no 
association between vitamin D intake and CHD death with RR 1.10 (95% confidence interval 
(CI) 1.04-1.17,p= 0.677) , CVD death 1.07( 95% CI 1.02-1.12, p=0.578), and total death RR 
1.05( 95% 1.00-1.10, p=0.266 (Table 4). The association remained insignificant after further 
adjustment for known confounders such as total serum cholesterol concentration, triglycerides 
concentration, BMI, diabetes mellitus, education and energy intake and diagnostic category 
(CABG or PTCA compared with AMI or AMIS).  
Table 4. Risk of death (95% confidence interval) with vitamin D intake adjusted for age and sex. 
Death  Risk ratio( 95% Confidence 
Interval) 
P value 
CHD death 1.10(1.04, 1.17) [16] 0.677 
CVD death 1.07(1.02,1.12) [19] 0.578 
Total death 1.05(1.00, 1.10) [34] 0.266 
 [ ] Number of deaths.
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There was no trend in hazard ratios across different groups of vitamin D intake for CHD 
mortality, CVD death and total deaths (p for trend across groups: 0.30, 0.74 and 0.89 
respectively). After adjustment for age, gender and other confounders, those in the dietary 
vitamin D group of  5-7 µg/day  had RR of 1.27 [95% (CI): 0.52,3.12) of  total death, compared 
to those in the lowest group (< 5 µg/day ) (p for trend across groups  0.30). After re-analyzing 
vitamin D intake in two groups (≤ 7 µg/day versus >7 µg/day) and all the endpoints, the results 
remained non significant. Detailed results are shown in table 5.  
 
 Table 5. Risk of death (95% confidence interval) with vitamin D intake in two and three 
categories. 
Death  < 5 µg/day      5 -  7 µg/day           >7 µg/day        P for 
trend 
Vitamin D ≤ 
7ug/day  vs >7 
ug/day  
CHD death 1 [8] 0.97 ( 0.41, 2.29 ) [2] 0.67 (0.23, 1.98 ) [6] 0.89 1.46 (0.70, 3.06 ) 
CVD death 1 [11] 1.06( 0.50, 2.25 ) [2] 0.59(0.21, 1.63 ) [6] 0.74 1.51 ( 0.79, 2.89 ) 
Total death 1 [21] 1.27(0.52,3.12 ) [6] 0.98(0.32,2.94 ) [7] 0.30 1.37( 0.67, 2.79 ) 
[N] Number of deaths in each tertile.  
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8. DISCUSSION 
8.1Vitamin D intake and mortality 
In contrast to most previous studies, the findings from this study demonstrate that there is no 
association between vitamin D intake and CHD mortality, and all cause mortality among men 
and women with CHD in Kuopio Finland after adjustment for age and sex. There results 
remained non significant after further adjustment for previously known CHD risk factors. 
 These findings are consistent with some, but not all previous studies, providing evidence that 
there is no association between vitamin D and CHD mortality. A previous study by Messenger 
and colleagues (2011) had similar findings (Messenger et al. 2011) but had more CHD events 
observed. This could be attributed to the larger number of participants. The study had 3094 male 
participants, with a mean age of 76.4 years. Our study participants had a mean age of 60 years. A 
meta analysis found no association in two studies between vitamin D intake at baseline, and 
increased risk for cardiovascular and all-cause mortality (Grandi et al. 2010). Another study 
concluded that a low vitamin D intake is not associated with CHD mortality (Cawthon et al. 
2010). The study had male participants aged at least 65 years, while our study had 415 male and 
female participants. There are also studies that have shown an association between vitamin D 
intake and CHD death. An example is a cohort study that provided evidence that inadequate 
amounts of vitamin D in the body may predict a higher risk of CHD death (Melamed et al. 2008).  
The relation between vitamin D and CHD is complex, and most studies including our study show 
no association between vitamin D intake and CHD mortality.  
Low vitamin D intake was noted in women. Similar findings were demonstrated in a study by 
Hirani et al. (2010), where 25(OH)D were significantly higher in men than in women. It was 
suggested that men consumed vitamin D from diet, or had more exposure to the sun than women. 
This makes women more susceptible to low 25(OH)D level. No association between 25(OH)D 
and all-cause mortality was observed, although men with lower 25(OH)D tended to have worse 
health status than men with higher 25(OH)D levels; however, these differences tended to be 
small in magnitude (Cawthon et al. 2010). For example, a higher percentage of women 
consumed lower amounts of vitamin D, while a higher percentage of men ate the recommended 
amounts of vitamin D. 
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A low vitamin D intake has continued to be associated with non communicable conditions such 
as CHD especially among the older population (Hirani et al. 2010). In our study, however, 
additional adjustment for age did not affect the predictive value of vitamin D intake with regard 
to mortality. Generally vitamin D intake in Europe is low at 2-3 µg/day, especially amongst the 
elderly (Ovesen et al. 2003). The FINDIET study reported that the average vitamin D intake 
levels still fall below the recommended amounts of 400 IU/day according to IOM (Institute of 
Medicine 2010, Pietinen et al. 2010). There has been no consensus on the RDA of vitamin D in 
the European region, mainly due to its dual nature in supply to the body. The amount obtained 
endogenously varies, making it difficult to have accurate recommendations. The RDA in most 
European countries is 5 to 10 µg/day with higher amounts recommended in the elderly and 
infants. Other studies suggest vitamin D intake of 50 to 100 µg/day (Vieth et al. 2001). In this 
study the mean vitamin D intake was 5.2 µg/day, which is slightly above the minimum 
recommended. The current Finnish recommendations for adults are 7.5µg/day and for subjects 
over 60 years, a supplement providing 20µg/day is recommended (Finnish National Nutritional 
Council 2012). 
As individuals age the concentration of 25(OH)D decreases due to the declining efficacy of the 
skin to produce vitamin D (Hirani et al. 2010, MacLaughlin & Holick 1985). This has been 
associated with immobility, low use of supplements and other age related diseases. The elderly 
spend less time exposed to sunlight especially those in institutions (Ovesen et al. 2003). The 
population in our study had a mean age of 60, making them susceptible to insufficient vitamin D 
intake. Increased BMI had increased odds of having a lower vitamin D status when compared to 
those with a lower BMI (Hirani et al. 2010). Low vitamin D intake could be a precursor to high 
BMI (Forman et al. 2007). A large population of the subjects in our study was overweight with a 
mean BMI of 28.2 kg/ m
2
. Other studies have continued to suggest that individuals with 
increased BMIs have a low vitamin D status due to body fat (Hirani et al. 2010).  
A study conducted in Finland revealed that vitamin D intake was low in 20% of hospitalized 
elderly men and 26% of hospitalized elderly women in Finland. The prevalence was lower in 
outpatients with 6% and 2% of men and women, respectively (Kauppinen-Makelin et al. 2001). 
Interestingly, low vitamin D levels are exhibited in healthy individuals during winter, with 
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25(OH)D concentrations reduced to <25 nmol/l in 26.2% of women and 28.6% of the men in 
Finland (Lamberg-Allardt et al. 2001).  
In summary, and in contrast to many but not all previously reported studies, vitamin D intake 
was not associated with an increased risk of all-cause or cause-specific CHD mortality. Dietary 
vitamin D does not protect an individual with CHD from death. Randomized trials are needed to 
determine the causal relation between vitamin D and mortality. 
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9. STRENGTHS AND LIMITATIONS 
The strengths of this study is that we had a representative sample of both men and women with a 
high participation rate, prospectively collected data and few losses during the follow up period. 
This then makes it possible to generalize the findings to the larger population in Kuopio, Finland, 
owing to the fact that CHD are common in this region of the country.  
The use of nationwide mortality register to obtain information on CHD using death certificates 
has been shown to have a reasonably good validity. Information on CHD and its risk factors at 
baseline was from the physicians examination. However the population in the study was rather 
small compared to other studies which could have affected the results of this study.  
The low number of deaths also reduces the power to find several associations. Data on several 
CHD risk factors facilitated adjustment for potential confounders but at the same time it can be 
speculated that individuals with chronic illnesses may have had reduced 25(OH)D concentrations 
because of limited exposure to the sun and inadequate dietary intake. This could suggest that 
vitamin D status is a non specific indicator of chronic illness rather than a direct contributor to 
the pathogenesis of disease. Vitamin D intake measurement was not repeated during follow up 
that might have led to different results. These findings can easily be generalized to the Finnish 
population with CHD and not to the wider population. 
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10. SUMMARY AND CONCLUSION 
In this study, there is no association between vitamin D intake and CHD. However, other studies 
have shown a positive correlation. Therefore, gaps still exist in identifying the relationship 
between vitamin D intake and CHD.  
The association between vitamin D intake and CHD mortality was non significant, after 
adjustment for age, sex and other confounders. Although there could be a possible causal link 
between vitamin D and CHD mortality, further investigations and studies from different 
populations is necessary for further clarification. The existence of a causal link between vitamin 
D intake and CHD mortality could be demonstrated in a randomized controlled clinical trial.  
In conclusion, the intake of vitamin D, may not have significant CHD related public health 
implications. However, more research on the health benefits of vitamin D intake and CHD would 
be recommended. Due to the role of CHD as a leading cause of death in developed countries, 
identification of new CHD risk factors is fundamental. 
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